While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.
The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...
RemeGen's disitamab vedotin with Junshi Pharma's Loqtorzi beat standard chemotherapy in first-line HER2-expressing metastatic urothelial cancer.
In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.
NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback